Our study is focused on the presence of elevated Apo B in the population of the SEPHAR registry and indicates that high Apo B may be considered as a risk factor for CVD, being associated with clinical or subclinical markers of atherosclerosis. This evidence concerns the gene APOB and atherosclerosis.